| Project/Area Number |
23590978
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
YAMASAKI Takahiro 山口大学, 医学(系)研究科(研究院), 教授 (00304478)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Naoki 山口大学, 大学教育機構, 講師 (90448283)
TERAI Shuji 山口大学, 大学院医学系研究科, 准教授 (00332809)
SAKAIDA Isao 山口大学, 大学院医学系研究科, 教授 (80263763)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 鉄キレート剤 / CDAAモデル / Deferasirox / Sorafenib / Deferoxamine / DEN肝発癌モデル / 肝細胞癌 / DEN発癌モデル / Deferoximine |
|---|
| Research Abstract |
Sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC). However, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator deferoxamine can prevent liver fibrosis and preneoplastic lesions. We investigated the influence of administering an oral iron chelator, deferasirox (DFX), on the effects of sorafenib. The combination of DFX+sorafenib markedly prevented liver fibrosis and preneoplastic lesions better than the other treatments. Furthermore, the combination therapy produced significantly fewer adverse effects such as body weight and hand-foot skin syndrome compared with the sorafenib group. The combination therapy with DFX and sorafenib may be a useful adjuvant therapy to prevent recurrence after curative treatment of HCC.
|
